arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

NEKTAR THERAPEUTICS

NKTR
$57.68 ▼ -3.32 (-5.44%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

NEKTAR THERAPEUTICS faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.9B
Dividend Yield
Revenue Growth -9.3%
Op. Margin -417.9%
ROIC -3.7%
FCF / Share $-2.30
Trailing P/E
Price / Book 1.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.13M
↓ -9.3%
Net Income Profit after all expenses
$-40.62M
↑ +2.3%
Operating Margin Operating profit as % of sales
-417.9%
↓ -16.2% 0th
FCF / Share Free cash flow per share
$-2.30
↓ -28.1%
Long-Term Debt Long-term obligations
$133.50M
↓ -1.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
3
Cash Quality
75

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters